The UK and US have established a important bilateral deal that will ensure zero import taxes on British pharmaceutical products going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase expenditure on medicines through the NHS. This pledge secures that import taxes on these crucial goods will be held at zero for a duration of three years.
This development comes after earlier threats to hike import taxes on patented pharmaceutical products, with figures floated as high as double the cost.
"This deal with the UK bolsters the worldwide climate for innovative medicines and brings much-needed fairness to American-British pharmaceutical trade," a release said.
Economic Impact
Drugs constitute one of the the United Kingdom's largest export categories to the America, which is clearly the primary destination for major British pharmaceutical firms.
Trade data indicate that in the year leading up to the third quarter, the UK shipped drugs worth £11.1bn to the US. This value made up 17.4% of British export trade in that span.
"This deal safeguards employment, boosts investment and paves the way for the UK to become a worldwide center for biotech and pharma," a minister commented.
Specific UK Commitments
The agreement involves several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be limited at 15%. In the past, repayments were more than twenty percent.
Industry Background
The deal follows a long-running dispute between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were intensified by arguments that American patients were charged significantly more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or abandoned, while major expansions have been directed toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on treatments, noting that its spending on drugs had decreased as a proportion of its resources over the previous ten-year period.
